Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects.
The renal, hormonal and haemodynamic effects of chronic (4 days) dosing with an inhibitor of endopeptidase EC 3.4.24.11 (UK 79300) were assessed in two groups, each of eight normal volunteers, receiving 25 mg every 12 h (group 1) or 100 mg every 12 h (group 2) of UK 79300 in double-blind, balanced-randomized, placebo-controlled, crossover studies. Group 2 (but not group 1) exhibited a significant transient natriuresis (P less than 0.01) and a consequent sustained negative cumulative sodium balance (70 +/- 21 mmol) which was established within 48 h and remained for the duration of dosing with UK 79300. Urine and plasma cyclic guanosine monophosphate (cGMP) levels rose significantly above placebo values (P less than 0.01 and P less than 0.001, respectively) in both groups and the effect was sustained throughout the dosing period. Plasma atrial natriuretic factor (ANF) was slightly enhanced by UK 79300 in group 1 (P less than 0.05) but not significantly increased in group 2. Despite a significant increase in heart rate in both groups (P less than 0.001) and of natriuresis in group 2, there was minimal evidence of renin-aldosterone activation in either group. Trends towards lower systolic pressures, observed in both groups, did not attain statistical significance. These findings suggest chronic treatment with UK 79300 induces an increase in tissue ANF levels, with sustained enhancement of plasma and urine concentrations of ANF second messenger (cGMP) and increased heart rate.
Richards
A M
AM
Department of Cardiology, Princess Margaret Hospital, Christchurch, New Zealand.
Wittert
G
G
Espiner
E A
EA
Yandle
T G
TG
Frampton
C
C
Ikram
H
H
D000450:Aldosterone / Q000652:urine; D000804:Angiotensin II / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000378:metabolism; D002940:Circadian Rhythm / Q000187:drug effects; D003404:Creatinine / Q000652:urine; D006152:Cyclic GMP / Q000652:urine; D004311:Double-Blind Method; D004702:Endocrine Glands / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007189:Indans / Q000494:pharmacology*; D007668:Kidney / Q000187:drug effects*; D009318:Natriuresis / Q000187:drug effects; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D011422:Propionates / Q000494:pharmacology*; D012016:Reference Values; D012083:Renin / Q000097:blood
D007189:Indans; D011422:Propionates; D000804:Angiotensin II; D000450:Aldosterone; D009320:Atrial Natriuretic Factor; C062766:candoxatril; D003404:Creatinine; D012083:Renin; D015260:Neprilysin; D006152:Cyclic GMP